These transactions were part of a routine process involving automatic sales to cover tax liabilities associated with restricted stock. After these transactions, Devers holds 15,937 common shares of Ionis. In addition, Devers was awarded 33,000 restricted stock and 22,000 performance-restricted stock, which may vest in the future based on specific performance criteria. According to InvestingPro data, analysts maintain a bullish outlook on the stock with a consensus recommendation of 1.84 (strong buy), and the company maintains a “decent” overall financial health score. For deeper insight into insider trading patterns and comprehensive analysis, InvestingPro offers detailed research reports covering over 1,400 US stocks, including IONS. According to InvestingPro data, analysts maintain a bullish outlook on the stock with a consensus recommendation of 1.84 (strong buy), and the company maintains a “decent” overall financial health score. For deeper insight into insider trading patterns and comprehensive analysis, InvestingPro offers detailed research reports covering over 1,400 US stocks, including IONS.
These transactions were part of a routine process involving automatic sales to cover tax liabilities associated with restricted stock. After these transactions, Devers holds 15,937 common shares of Ionis. In addition, Devers was awarded 33,000 restricted stock and 22,000 performance-restricted stock, which may vest in the future based on specific performance criteria.
In other recent news, Ionis Pharmaceuticals (NASDAQ: ) maintained its positive position at Piper Sandler and Needham, after the FDA approved olesarsen (TRYNGOLZA) for adults with familial chylomicronemia syndrome (FCS). The approval marks the first stand-alone commercial launch of Ionis Pharmaceuticals’ drug, priced at $595,000 per year, in line with expectations for treatments targeting ultra-rare diseases. The company plans to transition Open-Label Extension (OLE) and Expanded Access Program (EAP) patients to the commercial drug during the first half of 2025. Piper Sandler forecasts $37 million in US FCS revenue for fiscal 2025, while Needham maintains a Buy rating for Ionis.
Additionally, Ionis Pharmaceuticals recently reported third quarter 2024 financial results, with a focus on non-GAAP financials, indicating confidence in their operational management and long-term outlook. The company’s 2025 revenue forecast for TRYNGOLZA is $27 million, slightly below the current consensus estimate of $28 million. However, this may change with the expected future approval for the indication of severe hypertriglyceridemia.
Finally, Ionis expects positive results from key studies for the severe hypertriglyceridemia (sHTG) indication in the second half of 2025. Analysts at Needham and TD Cowen expressed confidence in the company’s market position and TRYNGOLZA’s potential. These recent developments highlight the progress and potential of Ionis Pharmaceuticals in the pharmaceutical industry.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
